Sustained Release Excipients Market Analysis & Forecast 2035: Growth Drivers and Industry Outlook
Sustained Release Excipients Market Outlook and Forecast
The Sustained Release Excipients Market is witnessing strong momentum as pharmaceutical manufacturers increasingly focus on improving drug efficacy, patient compliance, and controlled drug delivery systems. Sustained release excipients have become essential components in modern pharmaceutical formulations, enabling drugs to release active ingredients over an extended period while reducing dosing frequency and enhancing therapeutic outcomes. Growing demand for chronic disease management, advancements in formulation technologies, and increasing investments in innovative drug delivery platforms continue to strengthen market expansion worldwide.
The market is further supported by rising pharmaceutical R&D activities, the growing adoption of oral controlled-release formulations, and increasing regulatory emphasis on product quality and patient-centric therapies. Manufacturers are investing in advanced polymers, lipid-based carriers, and multifunctional excipients that improve stability, bioavailability, and manufacturing efficiency. In addition, partnerships between excipient suppliers and pharmaceutical companies are accelerating the commercialization of next-generation sustained-release products.
- 2025 Market Size: USD 1.56 Billion
- Projected 2035 Market Size: USD 3.49 Billion
- Growth Forecast (2026–2035): 8.4%
Regional Performance Highlights
North America remains a leading regional market owing to its advanced pharmaceutical manufacturing infrastructure, extensive clinical research activities, and increasing adoption of innovative drug delivery technologies. Strong regulatory standards and high investments in specialty pharmaceuticals continue to support sustained demand for advanced excipients.
Europe benefits from a well-established pharmaceutical industry, continuous innovation in controlled-release formulations, and favorable regulatory frameworks promoting high-quality excipient development. Countries such as Germany, France, Switzerland, and the UK continue to invest in pharmaceutical innovation.
Asia Pacific is experiencing significant expansion due to rapid pharmaceutical manufacturing growth, increasing healthcare expenditure, rising generic drug production, and expanding contract manufacturing organizations (CMOs). China, India, Japan, and South Korea are emerging as important production and innovation hubs.
Market Segment Analysis
By Material Type: The Polymers segment held a 47.59% share of the sustained release excipients market in 2025. Polymer-based excipients continue to dominate due to their excellent controlled-release capabilities, formulation flexibility, and compatibility with various active pharmaceutical ingredients.
By Technology: The Targeted Delivery segment accounted for a 24.6% share in 2025, making it the leading technology segment. Increasing focus on site-specific drug delivery, reduced systemic side effects, and enhanced therapeutic efficiency continues to drive adoption across multiple therapeutic areas.
Request Free Sample Report @ https://www.fundamentalbusinessinsights.com/request-sample/14921
Top Market Trends Transforming the Sustained Release Excipients Market
Growing Adoption of Advanced Polymer Technologies
Advanced polymer technologies continue to reshape sustained release excipient development. Pharmaceutical companies are increasingly utilizing biodegradable, bio-compatible, and multifunctional polymers that improve release kinetics while maintaining formulation stability. Hydrophilic and hydrophobic polymer combinations are also being developed to optimize drug release profiles for complex therapies.
Recent product innovations have focused on enhancing patient adherence by reducing dosing frequency while ensuring consistent therapeutic drug concentrations. These innovations are particularly valuable in chronic disease treatments including cardiovascular disorders, diabetes, neurological diseases, and oncology.
Increasing Focus on Patient-Centric Drug Delivery
Patient-centric healthcare has become a significant market driver. Pharmaceutical manufacturers are designing sustained release formulations that simplify treatment regimens and improve medication adherence. Longer-lasting oral dosage forms reduce the burden of multiple daily doses, improving clinical outcomes and patient satisfaction.
The demand for customized drug delivery systems is encouraging excipient manufacturers to develop highly versatile materials suitable for tablets, capsules, injectable formulations, and implantable drug delivery systems.
Expansion of Targeted Drug Delivery Technologies
Targeted delivery systems are gaining widespread acceptance across pharmaceutical research. Sustained release excipients are increasingly incorporated into formulations that deliver active ingredients directly to specific tissues or organs while minimizing adverse effects. This trend supports precision medicine initiatives and enables improved therapeutic performance across multiple disease categories.
Research institutions and pharmaceutical companies continue to collaborate on advanced nanoparticle-based delivery systems, lipid carriers, and polymer matrices that further enhance targeted drug release.
Digitalization and Smart Pharmaceutical Manufacturing
Digital manufacturing technologies are improving excipient production through process automation, predictive quality monitoring, artificial intelligence, and real-time analytical tools. Pharmaceutical manufacturers are integrating continuous manufacturing techniques that increase production efficiency while ensuring consistent excipient quality.
The implementation of Quality by Design (QbD) principles and advanced process analytical technologies is helping manufacturers optimize formulation development while meeting increasingly stringent global regulatory requirements.
Request Free Sample Report @ https://www.fundamentalbusinessinsights.com/request-sample/14921
Recent Company Developments
Colorcon continued expanding its modified release excipient portfolio through formulation support services and innovative coating technologies that improve controlled drug release performance.
Ashland Inc. strengthened its pharmaceutical excipient offerings by expanding technical collaboration with drug manufacturers focused on controlled-release formulations and bioavailability enhancement.
DuPont continued investing in advanced pharmaceutical materials designed to support sustained release applications while improving formulation consistency and manufacturing efficiency.
Roquette Frères expanded research activities focused on plant-based pharmaceutical excipients and multifunctional ingredients suitable for next-generation oral drug delivery systems.
Evonik Industries AG introduced additional formulation capabilities supporting controlled-release oral dosage forms while expanding partnerships with pharmaceutical innovators developing complex drug delivery platforms.
BASF SE continued strengthening its pharmaceutical solutions portfolio through ongoing investments in specialty polymers and excipient technologies supporting sustained and targeted drug delivery.
DFE Pharma expanded its pharmaceutical excipient solutions with increased emphasis on high-quality functional excipients that support controlled-release formulation development.
Croda International Plc advanced lipid-based excipient innovations designed to improve drug solubility, sustained release performance, and overall therapeutic effectiveness.
Lubrizol Life Science Health continued enhancing its pharmaceutical polymer technologies with new formulation support services focused on controlled drug release and advanced oral dosage systems.
SPI Pharma expanded its functional excipient portfolio while strengthening global supply capabilities to support growing pharmaceutical demand for sustained-release formulations.
Over the past year, industry participants have increasingly focused on strategic collaborations, manufacturing capacity expansion, regulatory compliance, sustainable production practices, and innovative excipient technologies to address evolving pharmaceutical requirements worldwide.
Request Free Sample Report @ https://www.fundamentalbusinessinsights.com/request-sample/14921
Related Reports
About Fundamental Business Insights:
Fundamental Business Insights is global market research and consulting company which is engaged in providing in depth market reports to its various types of clients like industrial sectors, financial sectors, universities, non-profit, and corporations. Our goal is to offer the correct information to the right stakeholder at the right time, in a format that enables logical and informed decision making. We have a team of consultants who have experience in offering executive level blueprints of markets and solutions. Our services include syndicated market studies, customized research reports, and consultation.
Contact us:
Robbin Fernandez
Head of Business Development
Fundamental Business Insights and Consulting
Email: sales@fundamentalbusinessinsights.com
